Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings

For the quarter ended December 2023, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.01 billion, up 4.1% over the same period last year. EPS came in at $5.02, compared to -$0.07 in the year-ago quarter.The reported revenue represents a surprise of +0.37% over the Zacks Consensus Estimate of $1.01 billion. With the consensus EPS estimate being $5.26, the EPS surprise was -4.56%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to dete ...